Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kianzad (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands), L. Celant (Amsterdam, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), L. Handoko (Amsterdam, Netherlands), H. Bogaard (Amsterdam, Netherlands). Precapillary pulmonary hypertension in patients with a high HFpEF probability: Insights from the Amsterdam UMC PAH-cohort. 1516

Member's Comments

No comment yet.

Related content which might interest you:

• The impact of anti-IgE treatment on the airway microbiome in asthma.
• Quality Improvement in a Sleep Clinic: To increase the capacity and reduce the time to treatment for patients with Obstructive Sleep Apnoea
• Endoscopic lung volume reduction with endobronchial valves in very low DLCO patients